Hepatocellular carcinoma (HCC) is an aggressive human cancer with increasing incidence
worldwide. Multiple efforts have been made to explore pharmaceutical therapies to treat …

Cancer cells alter metabolic processes to sustain their characteristic uncontrolled growth
and proliferation. These metabolic alterations include (1) a shift from oxidative …

The pentose phosphate pathway (PPP) branches from glucose 6-phosphate (G6P),
produces NADPH and ribose 5-phosphate (R5P), and shunts carbons back to the glycolytic …

Metastasis requires cancer cells to undergo metabolic changes that are poorly understood,–
. Here we show that metabolic differences among melanoma cells confer differences in …

Abstract Systems medicine has a mechanism-based rather than a symptom-or organ-based
approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In …

Metabolic reprogramming is one of the hallmarks of cancer. As nutrients are scarce in the
tumor microenvironment (TME), tumor cells adopt multiple metabolic adaptations to meet …

Hepatocellular carcinoma (HCC) invariably exhibits inadequate O2 (hypoxia) and nutrient
supply. Hypoxia-inducible factor (HIF) mediates cascades of molecular events that enable …

Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC).
However, the development of drug resistance is common. By using genome-wide …

In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and
stemness features. In this context, tumor cells might undergo cell fate transition in response …

Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC),
but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 …